Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471870 | 0.86 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL23975256 | 0.83 | MEN1 (0.43) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL26218120 | 0.83 | MEN1 (0.43) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL23594355 | 0.83 | MEN1 (0.43) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL26218118 | 0.83 | MEN1 (0.43) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL26218117 | 0.83 | MEN1 (0.43) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL21472047 | 0.82 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL21472076 | 0.82 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL23682905 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL21472075 | 0.81 | MEN1 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | KDM4E 2053/4885ALDH1A1 2958/4885MEN1 2058/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | KDM4E 2053/4885ALDH1A1 2958/4885MEN1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.